Navigation Links
SynCo Bio Partners Increases its Capacities by Expanding its Quality Team

AMSTERDAM, July 20 /PRNewswire/ -- SynCo Bio Partners B.V., the GMP contract manufacturer of biological-based vaccines and therapeutics, today announced that it had significantly expanded the number of clinical and commercial biopharmaceutical batches it is capable of releasing annually, whilst improving regulatory support continuity for its clients, with the addition of a second Qualified Person (QP) to its Quality Affairs team: Raoul Fisser

Raoul joined SynCo's Quality Affairs team from Astellas Pharma where he worked in Pharmaceutical Development, having previously gained experience in the Quality Assurance Department of the largest manufacturing site of Yamanouchi in Japan. He will now support SynCo's existing QP Rob Sprenkels, in the release of GMP batches of recombinant protein, polysaccharide and live-microbial-based bulk drug substances and final product. This addition reflects SynCo's growing client base and the solid business it has established.

'Raoul is an excellent addition to SynCo's Quality Affairs team and this expansion demonstrates the continuous growth in both client base and batch production at SynCo since our inception in 2000. Going forward, we look to supporting our clients in GMP production of an even wider range of novel biopharmaceuticals.' commented Pierre Warffemius, CEO of SynCo Bio Partners.

SynCo's expansion in batch release capabilities is a positive step in an ever increasingly competitive CMO market and is of special significance in the current global economic downturn. This development will allow SynCo to continue to grow revenues and to increase the number of GMP biopharmaceutical batches it can release each year.

For more information, please visit

About SynCo Bio Partners B.V.

SynCo Bio Partners is a GMP-licensed bulk drug substance and final product CMO with clinical and commercial production experience with mammalian and microbial systems. This experience has been acquired by developing new production processes for a number of international clients and producing a wide variety of different vaccines, live bacterial products and recombinant proteins in our state-of-the-art, GMP-licensed facilities since inception in 2000.

Focused solely on biopharmaceuticals, SynCo Bio Partners acts as a strategic, long-term partner delivering product on time to the highest quality standards. SynCo 's team are committed to exceeding customer expectations taking a truly collaborative approach to manufacturing.

SOURCE SynCo Bio Partners B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SynCo Bio Partners Wins Best Contract Manufacturing Organization 2009 ViE Award
2. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
3. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
4. Thomson Reuters Partners With Sagient Research
5. TransTech Services Partners, Inc. Shareholders Approve Plan of Liquidation; Company To Distribute Amounts in Trust
6. Essilor: Essilor Forges New Strategic Partnerships Around the World
7. ACT Announces Partnership With Gilead Sciences Inc.
8. New Leadership Team at International Trachoma Initiative to Build Stronger Partnerships to Eliminate Blinding Trachoma
9. Air Force Chief Master Sergeant Rod McKinley (U.S. Air Force Retired) Joins MicroTech as Vice President of Strategic Partnerships
10. MIT is pleased to announce that it has received a US$ 500,000 private placement from its Chinese partners
11. Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM)
Post Your Comments:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
(Date:3/22/2016)... OTTAWA, Ontario , PROVO ... 2016 Newborn Screening Ontario (NSO), which operates ... for molecular testing, and Tute Genomics and ... process management technology respectively, today announced the launch of ... new next-generation sequencing (NGS) testing panel. ...
Breaking Biology News(10 mins):